Xiao Xiao
肖啸
Xiao Xiao is a Chinese biotech entrepreneur and gene-therapy scientist, best known as a co-founder, chairman, and chief scientist of Belief BioMed (信念医药) . The company secured approval for China's first hemophilia B gene-therapy drug, Xinjining®, in 2025, a milestone Xiao described as filling unmet clinical demand through frontier R&D . He has represented Belief BioMed in partnership talks, including a 2026 strategic collaboration with Grand Life Science Group . Beyond this role, elsewhere's corpus does not cover his personal background or prior career.
AI-generated — may contain errors, please verify.
Coverage
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.10, 2026.3.24
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners Weekly · Top 10 Portfolio News, Vol. 05, 2026.2.11
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 42, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 39, 2025
Staying with you to mark milestone moments for Qiming Venture Partners' portfolio companies
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Roundup Vol. 13, 2025
Following Qiming Venture Partners' portfolio companies' milestone moments with you
Qiming Venture Partners-Backed Belief BioMed Announces Approval of China's First Hemophilia B Gene Therapy Drug Xinjining®
As China's first independently developed gene therapy for hemophilia B, Xinjiuning® will offer patients a completely new treatment option, with the potential to free them from a lifetime of frequent intravenous injections and help them return to a life without constraints.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 11, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
